` Comparison: NYKD, PNEXF - Alpha Spread

N
NYKD
vs
PNEXF

Over the past 12 months, NYKD has underperformed PNEXF, delivering a return of -58% compared to the PNEXF's 0% growth.

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
NYKD
PNEXF
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Valuation
Growth
Profitability
Solvency
Comparing Valuation
Running a multi-layered valuation analysis to compare how attractive each stock is.
Comparing Growth
Financial growth, forecasts, volatility, and historical drawdowns.
Comparing Profitability
Margins, returns on capital, and the consistency of profitability.
Comparing Solvency
Debt levels, liquidity, interest coverage, and bankruptcy risk.
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

N
NYKD Intrinsic Value
4.026 NOK
Undervaluation 56%
Intrinsic Value
Price
PNEXF Intrinsic Value
Not Available
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
N
Nykode Therapeutics ASA
OSE:NYKD
1.752 NOK
Pharnext SCA
OTC:PNEXF
999 999.9999 USD
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
NYKD, PNEXF

NYKD
PNEXF
Add Stock
Revenue
www.alphaspread.com
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
N
Nykode Therapeutics ASA
Revenue
Pharnext SCA
Revenue

All metrics are calculated based on data from the last 10 years.

Profitability Comparison

Free Cash Flow
NYKD, PNEXF

NYKD
PNEXF
Add Stock
Free Cash Flow
www.alphaspread.com
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
N
Nykode Therapeutics ASA
OSE:NYKD
Pharnext SCA
OTC:PNEXF
What is Free Cash Flow?

Gross Margin

NYKD
0%
PNEXF
0%
LTM 3Y Avg 5Y Avg 10Y Avg
N
Nykode Therapeutics ASA
Pharnext SCA

Operating Margin

NYKD
-512.8%
PNEXF
-17 526.7%
LTM 3Y Avg 5Y Avg 10Y Avg
N
Nykode Therapeutics ASA
Pharnext SCA

Net Margin

NYKD
-322.5%
PNEXF
-21 040%
LTM 3Y Avg 5Y Avg 10Y Avg
N
Nykode Therapeutics ASA
Pharnext SCA

FCF Margin

NYKD
-607.8%
PNEXF
-15 953.3%
LTM 3Y Avg 5Y Avg 10Y Avg
N
Nykode Therapeutics ASA
Pharnext SCA

ROE

NYKD
-17.3%
PNEXF
114.6%
LTM 3Y Avg 5Y Avg 10Y Avg
N
Nykode Therapeutics ASA
Pharnext SCA

ROA

NYKD
-15%
PNEXF
-391.1%
LTM 3Y Avg 5Y Avg 10Y Avg
N
Nykode Therapeutics ASA
Pharnext SCA

ROIC

NYKD
-80.7%
PNEXF
3 092.9%
LTM 3Y Avg 5Y Avg 10Y Avg
N
Nykode Therapeutics ASA
Pharnext SCA

ROCE

NYKD
-25.6%
PNEXF
275.4%
LTM 3Y Avg 5Y Avg 10Y Avg
N
Nykode Therapeutics ASA
Pharnext SCA

Solvency Comparison

Balance Sheet Comparison

Stocks Performance

Stocks Performance
NYKD, PNEXF

Loading

Performance Gap
NYKD, PNEXF

Loading
NYKD
PNEXF
Difference
www.alphaspread.com

Performance By Year
NYKD, PNEXF

Loading
NYKD
PNEXF
Add Stock
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare NYKD to other stocks
Unlock Full Access to Alpha Spread
Create Free Account